# Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

> **NCT00051129** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 291 (actual)

## Conditions studied

- Macular Degeneration
- Maculopathy, Age-Related
- Age-Related Maculopathies
- Age-Related Maculopathy
- Maculopathies, Age-Related

## Interventions

- **DRUG:** Anecortave Acetate 15 mg sterile suspension
- **OTHER:** Anecortave Acetate Vehicle

## Key facts

- **NCT ID:** NCT00051129
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2012-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051129, "Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00051129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*